Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates resolving patent litigation related to Axsome’s product SUNOSI. The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hetero of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Hetero a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Strong Commercial Trajectory and Growth Potential Justify Buy Rating for Axsome Therapeutics
- Axsome Therapeutics: Strategic Positioning and Pipeline Strength Drive Buy Rating
- Axsome Therapeutics enters $570M term loan, revolving credit facility
- Axsome Therapeutics Secures $570M Loan with Blackstone
- Axsome Therapeutics price target lowered to $180 from $200 at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue